MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Consensus Recommendation of “Strong Buy” by Analysts

Share on StockTwits

Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price objective of $42.50 for the company and are anticipating that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also given MeiraGTx an industry rank of 59 out of 255 based on the ratings given to its competitors.

Several brokerages have commented on MGTX. Chardan Capital restated a “buy” rating and issued a $45.00 target price on shares of MeiraGTx in a research note on Monday, September 23rd. Zacks Investment Research upgraded MeiraGTx from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Wednesday, November 13th. ValuEngine downgraded shares of MeiraGTx from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Piper Jaffray Companies initiated coverage on shares of MeiraGTx in a research report on Tuesday, September 3rd. They issued an “overweight” rating and a $40.00 price objective for the company.

In other news, Director Nicole Seligman purchased 5,000 shares of MeiraGTx stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $16.31 per share, for a total transaction of $81,550.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $81,550. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 17.40% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in MGTX. Rhumbline Advisers boosted its stake in MeiraGTx by 5.6% during the third quarter. Rhumbline Advisers now owns 19,075 shares of the company’s stock valued at $304,000 after buying an additional 1,005 shares during the period. Bank of Montreal Can purchased a new stake in shares of MeiraGTx in the 2nd quarter valued at about $35,000. California State Teachers Retirement System raised its holdings in shares of MeiraGTx by 11.0% in the 3rd quarter. California State Teachers Retirement System now owns 26,679 shares of the company’s stock valued at $426,000 after acquiring an additional 2,644 shares in the last quarter. Meeder Asset Management Inc. boosted its position in shares of MeiraGTx by 2,168.0% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,334 shares of the company’s stock valued at $53,000 after acquiring an additional 3,187 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in shares of MeiraGTx during the 3rd quarter valued at about $72,000. 42.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MeiraGTx stock traded down $0.06 during trading hours on Thursday, reaching $19.96. The company had a trading volume of 158,264 shares, compared to its average volume of 163,899. MeiraGTx has a one year low of $8.53 and a one year high of $30.23. The business has a fifty day simple moving average of $16.04 and a 200 day simple moving average of $20.66. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.90 and a quick ratio of 6.90. The firm has a market cap of $750.42 million, a PE ratio of -4.55 and a beta of 2.22.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. The company had revenue of $3.58 million for the quarter. On average, research analysts forecast that MeiraGTx will post -2.22 EPS for the current year.

About MeiraGTx

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on MeiraGTx (MGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.